Risk factors that may influence the decision to pause treatment include: Being in the dose-escalation phase of GLP-1 therapy Experiencing active gastrointestinal symptoms (nausea, vomiting, bloating) Having known gastroparesis or other conditions affecting gastric emptying Taking concurrent medications that further delay gastric emptying (e.g., opioids) Undergoing procedures with higher aspiration risk (e.g., emergency surgery, airway surgery) If your anaesthetist or surgical team advises temporary cessation based on your individual risk assessment, the timing will depend on the specific medication: Daily injections (such as liraglutide): Typically paused 24 hours before surgery Weekly injections (such as semaglutide, dulaglutide): Often paused with the last dose given at least 7 days before surgery Oral semaglutide (Rybelsus): Usually paused 24 hours before surgery However, these timings may vary according to local NHS Trust protocols and individual clinical assessment
doi: 10.1177/0300060519826820 17 AschbacherKKornfeldSPicardMPutermanEHavelPJStanhopeKet al
BPC-157 performs best when the problem is biologically suited to tissue repair: tendon irritation, ligament sprain, muscle strain, fascia irritation, or gut mucosal inflammation
Add the $99 Precision Peptide Genetic Test after your first month to personalize your therapy
That is not evidence that CagriSema is safer only that it has not been through the labeling process
